Renal Research Institute, New York, NY 10065, USA.
Fresenius Medical Care North America, Waltham, MA 02451, USA.
Toxins (Basel). 2023 Jul 20;15(7):465. doi: 10.3390/toxins15070465.
Bisphenol A (BPA)-based materials are used in the manufacturing of hemodialyzers, including their polycarbonate (PC) housings and polysulfone (PS) membranes. As concerns for BPA's adverse health effects rise, the regulation on BPA exposure is becoming more rigorous. Therefore, BPA alternatives, such as Bisphenol S (BPS), are increasingly used. It is important to understand the patient risk of BPA and BPS exposure through dialyzer use during hemodialysis. Here, we report the bisphenol levels in extractables and leachables obtained from eight dialyzers currently on the market, including high-flux and medium cut-off membranes. A targeted liquid chromatography-mass spectrometry strategy utilizing stable isotope-labeled internal standards provided reliable data for quantitation with the standard addition method. BPA ranging from 0.43 to 32.82 µg/device and BPS ranging from 0.02 to 2.51 µg/device were detected in dialyzers made with BPA- and BPS-containing materials, except for the novel FX CorAL 120 dialyzer. BPA and BPS were also not detected in bloodline controls and cellulose-based membranes. Based on the currently established tolerable intake (6 µg/kg/day), the resulting margin of safety indicates that adverse effects are unlikely to occur in hemodialysis patients exposed to BPA and BPS quantified herein. With increasing availability of new data and information about the toxicity of BPA and BPS, the patient safety limits of BPA and BPS in those dialyzers may need a re-evaluation in the future.
双酚 A(BPA)基材料用于制造血液透析器,包括其聚碳酸酯(PC)外壳和聚砜(PS)膜。随着对 BPA 不良健康影响的担忧增加,对 BPA 暴露的监管变得更加严格。因此,越来越多的使用 BPA 替代品,如双酚 S(BPS)。了解在血液透析过程中通过透析器使用 BPA 和 BPS 暴露的患者风险非常重要。在这里,我们报告了从当前市场上的八种透析器中获得的浸出物和可浸出物中的双酚水平,包括高通量和中截流膜。利用稳定同位素标记内标物的靶向液相色谱-质谱策略为使用标准添加法进行定量提供了可靠的数据。在使用 BPA 和 BPS 含材料制造的透析器中检测到 BPA 的浓度范围为 0.43 至 32.82 µg/装置,BPS 的浓度范围为 0.02 至 2.51 µg/装置,除了新型 FX CorAL 120 透析器外。在血路对照和纤维素基膜中未检测到 BPA 和 BPS。根据目前建立的可耐受摄入量(6 µg/kg/天),安全裕度表明,暴露于本文定量的 BPA 和 BPS 的血液透析患者不太可能发生不良反应。随着有关 BPA 和 BPS 毒性的新数据和信息的可用性增加,这些透析器中 BPA 和 BPS 的患者安全限值可能需要在未来重新评估。